Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia

Journal of the National Cancer Institute

Volumn 91, Issue 24, 1999, Pages 2096-2101

  Gobbi, Helenice ^a   Dupont, William D ^a   Simpson, Jean F ^a   Plummer Jr , W Dale ^a   Schuyler, Peggy A ^a   Olson, Sandra J ^a   Arteaga, Carlos L ^a   Page, David L ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST EPITHELIUM; CANCER INVASION; CANCER RISK; CASE CONTROL STUDY; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIUM HYPERPLASIA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0033572467     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.24.2096     Document Type: Article

References (50)

1. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51.
2. Dupont WD, Pari FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993; 71:1258-65.
3. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992; 267:941-4.
4. Arteaga CL, Dugger TC, Hurd SD. The multifunctional role of transforming growth factor (TGF)-betas on mammary epithelial cell biology. Breast Cancer Res Treat 1996;38:49-56.
5. Brattain MG, Markowitz SD, Willson JK. The type II transforming growth factor-beta receptor as a tumor-suppressor gene. Curr Opin Oncol 1996;8:49-53.
6. Reiss M, Barcellos-Hoff MH. Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 1997;45: 81-95.
7. Page DL, Anderson TJ, Rogers LW. Epithelial hyperplasia. In: Page DL, Anderson TJ, editors. Diagnostic histopathology of the breast. Edinburgh (Scotland): Churchill-Livingstone; 1987. p. 120-56.
8. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994;370:341-7.
9. Amendt C, Schirmacher P, Weber H, Blessing M. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 1998;17:25-34.
10. Kim IY, Ahn HJ, Lang S, Oefelein MG, Oyasu R, Kozlowski JM, et al. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 1998;4:1625-30.
11. Ko Y, Banerji SS, Liu Y, Li W, Liang J, Soule HD, et al. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells. J Cell Physiol 1998;176:424-34.
12. MacKay SL, Auffenberg T, Tannahill CL, Ksontini R, Josephs MD, Nowak M, et al. Transfection of the type II TGF-beta receptor into colon cancer cells increases receptor expression, inhibits cell growth, and reduces the malignant phenotype. Ann Surg 1998;227: 781-9.
13. Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, et al. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 1994; 269:26449-55.
14. Dupont WD, Page DL. Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol 1989;20: 723-5.
15. Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994;331:10-5.
16. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984;40:63-75.
17. Palli D, Rosselli del Turco M, Simoncini R, Bianchi S. Benign breast disease and breast cancer: a case-control study in a cohort in Italy. Int J Cancer 1991;47:703-6.
18. de Boer WI, Schuller AG, Vermey M, van der Kwast TH. Expression of growth factors and receptors during specific phases in regenerating urothelium after acute injury in vivo. Am J Pathol 1994;145:1199-207.
19. Gold LI, Sung JJ, Siebert JW, Longaker MT. Type I (RI) and type II (RII) receptors for transforming growth factor-beta isoforms are expressed subsequent to transforming growth factor-beta ligands during excisional wound repair. Am J Pathol 1997;150:209-22.
20. Roy SK, Kole AR. Transforming growth factor-beta receptor type II expression in the hamster ovary: cellular site(s), biochemical properties, and hormonal regulation. Endocrinology 1995;136:4610-20.
21. Lawless JF. Statistical models and methods for lifetime data. New York (NY): John Wiley & Sons; 1982.
22. McCullagh P, Neider JA. Generalized linear models. New York (NY): Chapman & Hall; 1989.
23. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of casecontrol studies. Lyon (France): IARC Sci Publ; 1980.
24. Clayton D, Hills M. Statistical models in epidemiology. Oxford (U.K.): Oxford University Press; 1993.
25. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia (PA): Lippincott-Raven; 1998.
26. SAS Institute Inc. The SAS system for windows. Release 6.12. Cary (NC): SAS Institute Inc.; 1996.
27. StataCorp. Stata Statistical Software. Release 6.0. College Station (TX): Stata Corporation; 1999.
28. Breslow NE, Day NE. Statistical methods in cancer research. Vol. II. The design and analysis of cohort studies. Lyon (France): IARC Sci Publ; 1987.
29. Heston JF, Kelly JAB, Meigs JW, Flannery JT. Forty-five years of cancer incidence in Connecticut: 1935-79. National Cancer Institute Monograph 70. Bethesda (MD): Department of Health and Human Services, 1986 (NIH Publ No. 86-2652).
30. Slyblo TM, Wood WC. Traditional prognostic factors in breast cancer. In: Bland KI, Copeland EM, editors. The breast: comprehensive management of benign and malignant diseases. Philadelphia (PA): Saunders; 1998. p. 419-26.
31. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6.
32. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994;219:332-41.
33. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
34. Rohan TE, Hartwick W, Miller AB, Kandel RA. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 1998;90: 1262-9.
35. Allred DC, Hilsenbeck SG. Biomarkers in benign breast disease: risk factors for breast cancer. J Natl Cancer Inst 1998;90:1247-8.
36. Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, et al. p53 mutations in benign breast tissue. J Clin Oncol 1995;13: 2293-300.
37. O'Malley FP, Vnencak-Jones CL, Dupont WD, Pari F, Manning S, Page DL. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab Invest 1994;71:67-72.
38. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Witlenbel KD, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995;1: 1257-60.
39. Lawrence JA, Merino MJ, Simpson JF, Manrow RE, Page DL, Steeg PS. A high-risk lesion for invasive breast cancer, ductal carcinoma in situ, exhibits frequent overexpression of retinoid X receptor. Cancer Epidemiol Biomarkers Prev 1998;7:29-35.
40. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997;6:297-301.
41. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993;92: 2569-76.
42. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268:1336-8.
43. Sun P, Dong P, Dai K, Hannon GJ, Beach D. p53-independent role of MDM2 in TGF-beta 1 resistance. Science 1998;282:2270-2.
44. Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK. Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 1988;48:3898-904.
45. Capocasale RJ, Lamb RJ, Vonderheid EC, Fox FE, Rook AH, Nowell PC. et al. Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sezary patients. Proc Natl Acad Sci USA 1995;92:5501-5.
46. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 1994;91:6002-6.
47. Pierce DF Jr, Gorska AE, Chytil A, Meise KS, Page DL, Coffey RJ Jr, et al. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci USA 1995;92:4254-8.
48. Lynch MA, Nakashima R, Song H, DeGroff VL, Wang D, Enomoto T, et al. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res 1998;58:4227-32.
49. Lazzereschi D, Ranieri A, Mincione G, Taccogna S, Nardi F, Colletta G, Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein. Cancer Res 1997;57:2071-6.
50. Koli KM, Arteaga CL. Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells. Cancer Res 1997;57:970-7.